The major catalyst is release of the data for the Psychotic Depression phase 3 trial in the second quarter of 2014.
My sense is they will make an announcement that the trial is fully enrolled in the first quarter ;either January or early February. From there it is probably a 30-45 day wait for the release of the results.
If the news is positive it transforms the company and moves it to double digits.
Also the year end conference call the first week of February will confirm the acceleration of sales for Korlym in Cushings. The CFO mentioned on the call that they believe they can reach cash flow break even without raising future capital. Key take away from the CC. Also the CEO stated "now is the time to buy Corcept". This guy is usually so low key but finally he is excited.
Finally they will announcing data at the Breast Cancer Meeting next week from a phase 1 trial of Korlym use in triple negative breast cancer. Cort just licensed this indication from the university of Chicago medical center.
Will start to get interesting here soon.As you know biotech stocks run up before data releases. Wall Street will start upgrading the stock after year end call into the phase 3 release. I have a significant position in the stock. L